24th Sep 2025 16:54
Animalcare Group PLC - York, England-based veterinary services and pharmaceuticals firm - Enters into agreement with 272Bio Ltd to develop and commercialise a novel biological treatment for sweet itch in equines, a group of mammals that includes horses, donkeys and zebras. Sweet itch, which is a common condition among equines, affects around 8% of horses globally. Animalcare adds that the annual addressable market is estimated to be worth between EUR150 million and EUR200 million globally. "The programme is at an early stage and will initially focus on preclinical research with the aim of achieving proof of concept over the next 18-24 months," it says. Read More
